Great paper !!! had a busy day and just got to read it with a good cup of coffee.
Some of my highlights:
The restoration to healthy levels of IL-6 and the restoration of the CD4/CD8 ratio for the majority of patients is just amazing.
The plasma viral load is going down for all patients, would like to se what do they look like after day 21.
"In line with the decrease of IL-6 protein levels observed in plasma, IL-6 transcripts were downregulated between day 0 and day 7 in monocytes, consistent with reports of monocyte/macrophages repolarization following CCR5 blockade"
The conclusion:
it would take a monkey not to understand that this has been proven beyond any doubt !!!
So we have:
Modulation of hemostasis
Immunomodulatory effects on inflammation (restoration of T cell lymhocytopenia).
Monocyte/macrophages repolarization
Reduced COVID plasma viremia
Who can do this ??? Who has a drug ready that can do this ?? Who has demonstrated that can do this ???
How much is this worth(in human lives) ??
Are there any doubts ??? Not on my mind. Would like to see more information on the hemostasis front and latter data on the plasma viral load but, in general, this study "throw it out of the park".
If, afer reading this paper, anybody has any doubts about Leronlimab role in COVID, you should not be here and should not be investing in CYDY or otherwise.
Some of my highlights:
The restoration to healthy levels of IL-6 and the restoration of the CD4/CD8 ratio for the majority of patients is just amazing.
The plasma viral load is going down for all patients, would like to se what do they look like after day 21.
"In line with the decrease of IL-6 protein levels observed in plasma, IL-6 transcripts were downregulated between day 0 and day 7 in monocytes, consistent with reports of monocyte/macrophages repolarization following CCR5 blockade"
Quote:Recent studies have found that a significant number of COVID-19 patients experience increased risks of strokes, blood clots and other thromboembolic events21. Platelet activation, which leads to the initiation of the coagulation cascade, can be triggered by chemokines including CCL5, suggesting that leronlimab treatment may be beneficial beyond its immunomodulatory effects on inflammation and hemostasis in COVID-19 patients.
The conclusion:
Quote:In summary, we show here for the first time, involvement of the CCL5-CCR5 axis in the pathology of SARS-CoV-2, and present evidence that inhibition of CCL5 activity via CCR5 blockade represents a novel therapeutic strategy for COVID-19 with both immunologic and virologic implications.
it would take a monkey not to understand that this has been proven beyond any doubt !!!
So we have:
Modulation of hemostasis
Immunomodulatory effects on inflammation (restoration of T cell lymhocytopenia).
Monocyte/macrophages repolarization
Reduced COVID plasma viremia
Who can do this ??? Who has a drug ready that can do this ?? Who has demonstrated that can do this ???
How much is this worth(in human lives) ??
Are there any doubts ??? Not on my mind. Would like to see more information on the hemostasis front and latter data on the plasma viral load but, in general, this study "throw it out of the park".
If, afer reading this paper, anybody has any doubts about Leronlimab role in COVID, you should not be here and should not be investing in CYDY or otherwise.
15
